IsoRay Medical continues to expand market adoption of Cesium-131 during third quarter 2007
RICHLAND, WA—IsoRay Medical, Inc. continues to broaden medical center acceptance of Cesium-131 as a brachytherapy treatment for prostate cancer, adding 51 active sites for a total of 142 through March 23, 2007. These active sites are either revenue producing, in the process of getting licensed for Cesium-131, or are targeted and are in advanced discussions to adopt Cesium-131.
IsoRay, Inc. ("IsoRay") (OTCBB:ISRY) is a medical isotope company that focuses on brachytherapy solutions for prostate and other malignant tissue cancers through use of its proprietary Cesium-131 radioisotope.
The considerable increase from 91 to 142 active locations (through March 23, 2007 of the company’s 3rd quarter 2007) comes from the conversion of sites previously listed as “License in Process” sites to revenue generating sites. Of the 12 sites listed in fiscal 2nd quarter (see chart below), nine sites placed and received orders in the 3rd quarter and two will receive orders in April. The final site is added to the 27 new “License in Process” sites for 3rd quarter totaling 28. For the same period, 53 sites have been added to the “Pre-Licensing Process” for a total of 76.
“We are pleased with the continued momentum in the number of active locations, as well as their conversion to revenue producing centers for IsoRay. We are seeing the positive impact from the expansion of our sales team in December 2006 and January 2007,” said IsoRay Chairman and CEO Roger Girard.
IsoRay Vice President Lori Woods said IsoRay plans to continue increasing the sales force during the next three months to bring the total of Territory Managers to 14-15.
Girard said the continued development of IsoRay’s sales team coincides with the upcoming release of information about the safety and efficacy of IsoRay Medical’s Cesium-131 brachytherapy seeds at the American Brachytherapy Society’s (ABS) 28th Annual Meeting, April 28—May 1, 2007 in Chicago. Four submissions will be announced by key national and international opinion leaders in the brachytherapy market—providing sought after information regarding Cesium-131 brachytherapy seeds.
Licensing of Cs-131 |
Q2’07 |
Q3’07 |
Licensed & Ordering |
29 |
38 |
License in Progress |
12 |
28 |
Pre-licensing Process |
50 |
76 |
Total Pipeline |
91 |
142 |
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy. Because it delivers 90% of its dose in 33 days, Cesium-131 reduces the duration of normal tissue exposure as compared to the other isotopes available. IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay’s future expectations, including: the advantages of our Cesium131seed, future production capabilities, development of protocols for the use of our Cesium131 seed to treat cancers other than prostate cancer, the level of market share our seed may attain, and all other statements in this release, other than historical facts, are forward-looking statements. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, and our ability to enforce our intellectual property rights, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
###
Media Contacts:
IsoRay Inc.
Ralph Scahtzmair
IsoRay Medical, Inc.
rschatzmair@isoray.com
or
The Bartlett Group Public Relations
Barry Bartlett
206-285-0673
Cell: 206-335-4694
barry@bartlettgrouppr.com
IsoRay Medical, Inc. 877.4.ISORAY
350 Hills Street, Suite 106 509.375.1202 TEL
Richland, WA 99352 509.375.3473 FAX
www.isoray.com
www.cesium131.com
|
